

Research Article

Lactobacillus plantarum and *Lactobacillus brevis* Alleviate Intestinal Inflammation and Microbial Disorder Induced by ETEC in a Murine Model

Xuebing Han, Sujuan Ding , Yong Ma, Jun Fang , Hongmei Jiang, Yi Li, and Gang Liu 

College of Bioscience and Biotechnology, Hunan Agricultural University, Hunan Provincial Engineering Research Center of Applied Microbial Resources Development for Livestock and Poultry, Changsha, Hunan 410125, China

Correspondence should be addressed to Jun Fang; fangjun1973@hunau.edu.cn and Gang Liu; gangle.liu@gmail.com

Received 10 July 2021; Accepted 20 August 2021; Published 21 September 2021

Academic Editor: Guoku Hu

Copyright © 2021 Xuebing Han et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

The purpose of this research is to explore the positive effects of *Lactobacillus plantarum* and *Lactobacillus brevis* on the tissue damage and microbial community in mice challenged by Enterotoxigenic *Escherichia coli* (ETEC). Twenty-four mice were divided into four groups randomly: the CON group, ETEC group, LP-ETEC group and LB-ETEC group. Our results demonstrated that, compared with the ETEC group, the LP-ETEC and LB-ETEC groups experienced less weight loss and morphological damage of the jejunum. We measured proinflammatory factors of colonic tissue and found that *L. plantarum* and *L. brevis* inhibited the expression of proinflammatory factors such as IL- β , TNF- α , and IL-6 and promoted that of the tight junction protein such as claudin-1, occludin, and ZO-1. Additionally, *L. plantarum* and *L. brevis* altered the impact of ETEC on the intestinal microbial community of mice, significantly increased the abundance of probiotics such as *Lactobacillus*, and reduced that of pathogenic bacteria such as *Proteobacteria*, *Clostridia*, *Epsilonproteobacteria*, and *Helicobacter*. Therefore, we believe that *L. plantarum* and *L. brevis* can stabilize the intestinal microbiota and inhibit the growth of pathogenic bacteria, thus protecting mice from the gut inflammation induced by ETEC.

1. Introduction

Diarrhea induced by Enterotoxigenic *Escherichia coli* (ETEC) is a major challenge to newborn piglets and weaned piglets. The condition increases occurrences of morbidity and mortality, which results in huge economic losses in the global swine industry [1]. ETEC can colonize in the small intestine, increase the expression of proinflammatory factors, cause intestinal barrier damage, and eventually lead to the development of intestinal inflammation [2–4]. Previous studies have proven that probiotics are vital to prevent and treat cancer [5], inflammatory bowel disease (IBD) [6], irritable bowel syndrome [7], and other diseases. In addition, probiotics can counteract the inflammation caused by ETEC [8, 9]. Most notably, probiotics are considered the only effective feed additives that protect against pathogens. In view of the injury and economic losses caused by intestinal inflammation such as diarrhea, colorectal cancer, and IBD, it is neces-

sary to study probiotics, which are used as feed additives to inhibit pathogens and promote intestinal health.

Lactic acid bacteria, a kind of probiotic that exists in human and animal intestines, can enhance the immune system by inhibiting the expression of proinflammatory cytokines or promoting that of anti-inflammatory cytokines [10, 11]. *Lactobacillus plantarum* is a major species of lactic acid bacteria, with a variety of probiotic characteristics, gastrointestinal transport tolerance, and anti-inflammatory properties [12]. Previous studies have shown that the supplementation of *L. plantarum* in the diet can promote the gastrointestinal health of weaned piglets [13] and improve the antioxidant status and growth performance of piglets [14]. It is worth noting that studies on the effect of *L. plantarum* on various cancers are also being actively carried out [15, 16]. As a close relative of *L. plantarum*, *L. brevis* also has a variety of probiotic characteristics, including tolerance to acid and bile, adhesion to intestinal cells, and the ability to

survive through the gastrointestinal tract [17, 18]. These characteristics of *L. brevis* enable it to maintain the homeostasis of the intestine, improve the barrier function of intestinal epithelium under oxidative stress, and reduce intestinal inflammation in the mouse model [19, 20].

In this study, ETEC was used to induce intestinal inflammation in a mouse model. And we explored the protective effects of *L. plantarum* and *L. brevis* on the injury induced by ETEC in the murine model, observed the changes in the amounts of cytokines and tight junction proteins, and determined the effects of these two probiotics on intestinal flora.

2. Materials and Methods

2.1. Bacteria. The strains *Lactobacillus plantarum* GL17, *Lactobacillus brevis* AY858, and Enterotoxigenic *Escherichia coli* used in this study were stored in Hunan Agricultural University (Changsha, China). *L. plantarum* GL17 and *L. brevis* AY858 were cultured in MRS broth at 37°C for 24 hours, while ETEC was cultured in a Luria-Bertani liquid medium at 37°C for the same time. To quantify the colonies, the cultured bacterial fluid was transferred to the corresponding solid medium and incubated at 37°C for 24 hours. Then, the bacterial samples of both probiotics and ETEC were centrifuged and suspended in sterile normal saline solution at 5×10^{10} CFU/mL and 1×10^8 CFU/mL, respectively.

2.2. Animals and Experimental Design. The experiment was approved by the Animal Care and Use Committee of Hunan Agricultural University. Twenty-four eight-week-old ICR mice from the Shanghai Laboratory Animal Central (Changsha, China) were housed in a pathogen-free environment for seven days of adaptation. Then, the mice were divided into four groups randomly: the control group (CON), the ETEC group (ETEC), the *L. plantarum* GL17 treatment group (LP-ETEC), and the *L. brevis* AY858 treatment group (LB-ETEC). There were six mice in each group, and the basic diet and water for all mice were not limited. The experiment lasted for 21 days (Figure 1(a)). During the first 14 days of the experiment, the LP-ETEC group and the LB-ETEC group were given *L. plantarum* GL17 and *L. brevis* AY858, respectively, by gavage every day, while the control group and the ETEC group were given sterile saline every day. From the 15th day of the experiment, the ETEC group, LP-ETEC group, and LB-ETEC group were given ETEC by gavage until the end of the experiment. On the 21st day, all mice were killed, and a part of the jejunum was fixed in paraformaldehyde for histomorphological analysis, while the contents of the colon were collected and frozen in liquid nitrogen for the determination of microbial diversity.

2.3. Jejunum Histopathology. The jejunum samples fixed in the paraformaldehyde were dehydrated using ethanol gradient and embedded in paraffin. The samples were then stained with hematoxylin and eosin and observed under a microscope. The specific process is in accordance with methods used in previous research [21].

2.4. qPCR. The total RNA of frozen colonic tissue was extracted by TRIzol (Invitrogen, USA) according to the instruction. To determine the concentration of the extracted RNA, DNase I was used to treat RNA, and then, the concentration was determined by spectrophotometer at 260 nm. The primers used in the experiment are shown in Table 1, and the specific methods refer to a previous experiment [22]. Finally, the amplification reaction was carried out, and the calculation formula used to determine gene expression level refers to Ma et al. [23].

2.5. 16S Ribosomal RNA Amplicon Sequencing. To determine the diversity of microorganisms in the colonic contents, the microbial genomic DNA of colon contents was extracted by using the QIAamp DNA Stool Mini Kit firstly. Then, the concentration and purity of DNA were detected on 1% agarose gel, and the primers 357F (5'-ACTCCTACGGRAGGCAGCAG-3') and 806R (5'-GGACTACHVGGGTWTCTAAT-3') were used to amplify the V3-V4 region of 16S rDNA. After recovery and purification of PCR products, the library was prepared for sequencing analysis. Finally, the quality of off-machine data was controlled and optimized, and the composition of microbial communities was determined by OTU clustering. Moreover, the α diversity analysis was performed by mothur (Version 1.33.3).

2.6. Data Analysis. All of the data in the experiment are expressed as mean \pm standard deviation (SD) and analyzed by one-way ANOVA and Tukey's multiple comparison test to compare the differences between the four groups (SPSS 21 software). P value < 0.05 was regarded as a significant difference.

3. Results

3.1. *L. plantarum* and *L. brevis* Inhibit the Weight Loss Induced by ETEC. The results of weight are shown in Figure 1(b). Compared with the CON group, ETEC reduced the weight of mice significantly ($P < 0.05$). When treated with *L. plantarum* GL17 and *L. brevis* AY858, the weight of mice increased significantly ($P < 0.05$). The results showed that these two probiotics reduced weight loss in the mice.

3.2. *L. plantarum* and *L. brevis* Inhibit the Development of Intestinal Injury Induced by ETEC. The results of histologic examination (Figure 2) showed that the height of jejunal villi decreased significantly ($P < 0.05$) and the crypt depth increased significantly ($P < 0.05$) after ETEC attack. Compared with the ETEC group, the mice in the LP-ETEC group had increased villus heights and reduced crypt depth significantly ($P < 0.05$). Similar results were observed in the LB-ETEC group, with a slight increase in villus heights and a significant decrease in crypt depth ($P < 0.05$). These results indicated that both of those two probiotics can reduce the intestinal damage caused by ETEC, especially *L. plantarum* GL17, which made the LP-ETEC group return to the same level as the CON group.




FIGURE 1: Impact of *Lactobacillus plantarum* and *Lactobacillus brevis* on body weight. The experimental process (a) and body weight (b). Data are mean \pm SD ($n = 6$). Without a common letter mark indicates significant differences ($P < 0.05$).

TABLE 1: The primers for this study.

| Primer | Name | 5'→3' sequence |
|---------------|------------------|------------------------------|
| IL-1 β | IL-1 β _F | ATGAAAGACGGCACACCCAC |
| | IL-1 β _R | GCTTGTGCTCTGCTTGTGAG |
| TNF- α | TNF- α _F | ACCCTGGTATGAGCCCATATAC |
| | TNF- α _R | ACACCCATTCCCTTCACAGAG |
| IL-6 | IL-6_F | GAGGATACCACTCCCAACAGACC |
| | IL-6_R | AAGTGCATCATCGTTGTTTCATACA |
| Claudin-1 | Claudin-1_F | GGGGACAACATCGTGACCG |
| | Claudin-1_R | AGGAGTCGAAGACTTTGCACT |
| Occludin | Occludin_F | TTGAAAGTCCACCTCCTTACAGA |
| | Occludin_R | CCGGATAAAAAGAGTACGCTGG |
| ZO-1 | ZO-1_F | GATCCCTGTAAGTCACCCAGA |
| | ZO-1_R | CTCCCTGCTTGCACTCCTATC |
| Lysozyme | Lysozyme_F | GCCAAGGTCTAACAATCGTTGTGAGTTG |
| | Lysozyme_R | CAGTCAGCCAGCTTGACACCACG |
| Cryptidin | Cryptidin_F | TCAAGAGGCTGCAAAGGAAGAGAAC |
| | Cryptidin_R | TGGTCTCCATGTTTCAGCGACAGC |
| A20 | A20_F | AAACCAATGGTGATGGAAACTG |
| | A20_R | GTTGTCCCATTTCGTCATTCC |




FIGURE 2: Impact of *Lactobacillus plantarum* and *Lactobacillus brevis* on jejunum tissue damage induced by ETEC. Images of jejunal tissue in the CON (a), ETEC (b), LP-ETEC (c), and LB-ETEC (d) groups; villus height (e); and crypt depth (f) in the four groups. Data are mean \pm SD ($n = 6$). Without a common letter mark indicates significant differences ($P < 0.05$).

3.3. *L. plantarum* and *L. brevis* Affect Inflammation and Intestinal Barrier. The expressions of cytokines in the colonic tissues were measured (Figures 3(a)–3(f)). Compared with the CON group, lysozyme and cryptidin in the ETEC group decreased significantly ($P < 0.05$), while no significant difference was observed in that of IL-1 β , TNF- α , IL-6, and A20. When treated with *L. plantarum* GL17, lysozyme and cryptidin increased significantly ($P < 0.05$). Similarly, after the treatment of *L. brevis* AY858, a significant increase in lysozyme and cryptidin ($P < 0.05$) and a significant decrease in IL-6 ($P < 0.05$) were observed.

The expression of tight junction proteins is shown in Figures 3(g)–3(i). When attacked by ETEC, claudin-1 and occludin decreased significantly ($P < 0.05$), while ZO-1 remained almost unchanged. *L. plantarum* GL17 increased claudin-1 and occludin slightly, but there was no significant difference compared with the ETEC group. Similarly, no significant difference was observed in occludin between the LB-ETEC group and the ETEC group. However, compared with the ETEC group, claudin-1 in the LB-ETEC group increased significantly ($P < 0.05$).

3.4. *L. plantarum* and *L. brevis* Regulate Intestinal Microbes in Mice. The results of intestinal microorganism diversity are shown in Figure 4. After the ETEC challenge, the Sobs index, Shannon index, Simpson index, and PD-whole-tree index decreased significantly ($P < 0.05$). After the treatment of *L. plantarum* GL17 and *L. brevis* AY858, these indexes increased and returned to normal level, especially the Sobs index and Simpson index, which were significantly different from those of the ETEC group ($P < 0.05$). Furthermore, the Shannon index in the LB-ETEC group and the PD-whole-tree index in the LP-ETEC group were significantly different from those in the ETEC group ($P < 0.05$). Therefore, both of these two probiotics have obvious protective effects on

ETEC-induced decline of intestinal microbial diversity in mice.

At the phylum level, there are nine kinds of microorganisms in each of four groups, of which *Bacteroidetes*, *Firmicutes*, and *Proteobacteria* accounted for more than 86% of all microorganisms (Figure 5(a)). The abundance of *Bacteroidetes* in the CON, ETEC, LP-ETEC, and LB-ETEC groups was 62.1485%, 42.3336%, 43.6535%, and 53.8593%, respectively. *Firmicutes* accounted for 26.6949%, 40.0591%, 46.6572%, and 33.6746%, respectively. The *Proteobacteria* abundance was 8.4628%, 14.4314%, 6.6691%, and 8.7466%, respectively. After being challenged by ETEC, *Bacteroidetes* in mice decreased significantly ($P < 0.05$). In contrast, the abundance of *Proteobacteria* showed the opposite trend, which was significantly higher than that of the CON group ($P < 0.05$) (Figures 5(b) and 5(c)). However, when treated with *L. plantarum* GL17 and *L. brevis* AY858, *Proteobacteria* in mice decreased significantly ($P < 0.05$).

The abundance of *Bacteroidia*, *Clostridia*, and *Bacilli* accounted for more than 80% of all microorganisms in the class level (Figure 6(a)). The abundance of *Bacteroidia* in the CON, ETEC, LP-ETEC, and LB-ETEC groups was 52.562%, 49.0004%, 52.9771%, and 51.7049%, respectively. *Clostridia* accounted for 16.7878%, 23.7975%, 14.2299%, and 14.7012%, respectively. The *Bacilli* abundance was 11.3105%, 10.0499%, 17.1775%, and 16.7497%, respectively. After being attacked by ETEC, the abundance of *Clostridia* and *Epsilonproteobacteria* increased, especially *Epsilonproteobacteria*, which increased significantly ($P < 0.05$) (Figures 6(b) and 6(c)). However, both *L. plantarum* GL17 and *L. brevis* AY858 significantly reduced the abundance of *Clostridia* and *Epsilonproteobacteria* ($P < 0.05$).

As for the order level, the abundance of *Bacteroidales*, *Clostridiales*, and *Lactobacillales* was the highest in the CON, LP-ETEC, and LB-ETEC groups (Figure 7(a)). The




FIGURE 3: Impact of *Lactobacillus plantarum* and *Lactobacillus brevis* treatment on the expressions of cytokines and tight junction protein. 1The relative gene expression level determined by qPCR of (a) IL-1 β , (b) TNF- α , (c) IL-6, (d) A20, (e) lysozyme, (f) cryptidin, (g) claudin-1, (h) occludin, and (i) ZO-1. Data are mean \pm SD ($n = 6$). Without a common letter mark indicates significant differences ($P < 0.05$).

abundance of *Bacteroidales* in the CON, LP-ETEC, and LB-ETEC groups was 50.562%, 39.1805%, and 39.7049%, respectively. *Clostridiales* accounted for 17.1168%, 14.2299%, and 16.8516%, respectively. The abundance of *Lactobacillales* was 17.2176%, 22.0299%, and 21.248%, respectively. However, the top three most abundant microorganisms at the order level in ETEC group were *Bacteroidales*, *Clostridiales*, and *Campylobacteriales*, accounting for 49.0004%, 25.221%, and 7.6303%, respectively. *Clostridiales* in the ETEC group increased significantly ($P < 0.05$) and *Lactobacillales* in the ETEC group decreased significantly ($P < 0.05$) compared with those in the CON group (Figures 7(b) and 7(c)). After the treatment of *L. plantarum* GL17 and *L. brevis* AY858, the abundance of *Clostridiales* and *Lactobacillales* had changed significantly ($P < 0.05$).

Eight representative microbial genera in the four groups were selected and analyzed (Figure 8(a)). In the genus of

microorganisms that have been classified, *Lactobacillus*, *Bacteroides*, and *Helicobacter* were the three main microorganisms among the groups of CON, LP-ETEC, and LB-ETEC. The abundance of *Lactobacillus* in the CON, LP-ETEC, and LB-ETEC groups was 26.08%, 33.5332%, and 27.7802%, respectively. *Bacteroides* accounted for 7.4573%, 23.1571%, and 9.449%, respectively. The abundance of *Helicobacter* was 1.486%, 2.9112%, and 3.2437%, respectively. However, the top three most abundant microbial genera in the ETEC group were *Bacteroides*, *Helicobacter*, and *Alloprevotella*, accounting for 5.9428%, 8.0295%, and 4.6711%, respectively. After being challenged by ETEC, the abundance of *Lactobacillus* reduced significantly ($P < 0.05$), while that of *Helicobacter* increased significantly ($P < 0.05$) (Figures 8(b) and 8(c)). However, when treated with *L. plantarum* GL17 and *L. brevis* AY858, the abundance of *Lactobacillus* and *Helicobacter* changed significantly ($P < 0.05$) and returned to the normal level.




FIGURE 4: Impact of *Lactobacillus plantarum* and *Lactobacillus brevis* treatment on intestinal microbial diversity. (a) Sobs index; (b) Shannon index; (c) Simpson index; (d) PD-whole-tree index. Data are mean \pm SD ($n = 6$). Without a common letter mark indicates significant differences ($P < 0.05$).

4. Discussion

The protective effects of *L. plantarum* GL17 and *L. brevis* AY858 on the injury induced by ETEC were explored in this study. The results showed that both probiotics reduced the weight loss and morphological damage of the jejunum significantly. The expression of cytokines decreased, while that of the tight junction protein increased in mice treated with *L. plantarum* GL17 and *L. brevis* AY858. Meanwhile, *L. plantarum* GL17 and *L. brevis* AY858 restored the colonic microbial diversity to the normal level in mice challenged by ETEC and increased the relative abundance of *Lactobacillus*. In contrast, *L. plantarum* GL17 and *L. brevis* AY858 reduced the relative abundance of *Proteobacteria*, *Clostridia*, *Epsilonproteobacteria*, and *Helicobacter* in the colon after ETEC challenge.

The surface of intestinal mucosa, which is the largest surface of the human body, contacts with the external environment continuously [24]. Columnar epithelial cells are arranged into the intestinal epithelium and folded into crypts or concave [25]. These fully differentiated epithelial cells protect the body from potentially harmful microorganisms and viruses in the intestinal microenvironment [26]. Intestinal villi are critical components of the intestine that can increase the absorption area and promote the absorption of nutrients [27]. Endotoxin produced by ETEC can cause a variety of morphological changes of the intestinal tract, such as the increase of mucosal crypt depth, decrease of villus height, and submucosal edema [28]. Probiotics can reduce

the morphological damage caused by the endotoxin, which can increase the height of villi and promote the growth of piglets [29, 30]. A previous study has shown that piglets fed with *L. plantarum* displayed higher villus height and lower crypt depth in the jejunum [1]. The same results were obtained in this experiment. *L. plantarum* and *L. brevis* protected the structural integrity of the jejunum, as well as the ability of absorbing nutrients. However, the protective effect of these two probiotics on villi is slightly different; *L. plantarum* is better than *L. brevis* at restoring the height of intestinal villi.

ETEC produces heat-labile enterotoxin (LT), and the LTA subunit of it, together with ADP-ribosylation factor, can induce the ribosylation of Gs α [31]. At that time, the adenylate cyclase of the target cell is uncontrolled, converting ATP to cAMP continuously. The increase of cAMP will not only activate the NF- κ B signaling pathway and produce a large number of inflammatory factors [32] but also activate the MAPK signaling pathway, resulting in the dislocation of tight junction proteins and impairment of intestinal barrier function [33]. The increase of proinflammatory factors, including IL-1 β , TNF- α , and IL-6, will aggravate intestinal inflammation and promote the occurrence of colorectal cancer. In this experiment, although the difference was insignificant, the proinflammatory factors showed an upward trend after ETEC challenge, which indicated that ETEC increased intestinal inflammation in mice. Probiotics can reduce the inflammatory response by reducing the level of cytokines [12, 34, 35], which is also proven by our research. Although




FIGURE 5: Impact of *Lactobacillus plantarum* and *Lactobacillus brevis* treatment on the microorganisms at the phylum level. (a) Relative abundance of microorganisms in the four groups at the phylum level; (b) abundance of *Bacteroidetes* in each of four groups; (c) abundance of *Proteobacteria* in each of four groups. Data are mean \pm SD ($n = 6$). Without a common letter mark indicates significant differences ($P < 0.05$).




FIGURE 6: Impact of *Lactobacillus plantarum* and *Lactobacillus brevis* treatment on the microorganisms at the class level. (a) Relative abundance of microorganisms in the four groups at the class level; (b) abundance of *Clostridia* in each of four groups; (c) abundance of *Epsilonproteobacteria* in each of four groups. Data are mean \pm SD ($n = 6$). Without a common letter mark indicates significant differences ($P < 0.05$).

the difference was not significant, the proinflammatory factors in mice treated with *L. plantarum* and *L. brevis* showed a decreasing trend. Previous researches conducted *in vitro* have shown that ETEC can reduce the amounts of occludin in Small Intestinal Epithelial Cell Line- (IPEC-) 1 entero-

cytes of piglets [36], the permeability of tight junctions in IPEC-J2 enterocytes of piglets [37], and dislocation of ZO-1 Caco-2 cells of human [38]. However, probiotics increased the expression of tight junction proteins such as ZO-1, claudin-1, and occludin to protect cells [36, 39]. In this




FIGURE 7: Impact of *Lactobacillus plantarum* and *Lactobacillus brevis* treatment on the microorganisms at the order level. (a) Relative abundance of microorganisms in the four groups at the order level; (b) abundance of *Clostridiales* in each of four groups; (c) abundance of *Lactobacillales* in each of four groups. Data are mean \pm SD ($n = 6$). Without a common letter mark indicates significant differences ($P < 0.05$).




FIGURE 8: Impact of *Lactobacillus plantarum* and *Lactobacillus brevis* treatment on the microorganisms at the genus level. (a) Relative abundance of microorganism in the four groups at the genus level; (b) abundance of *Lactobacillus* in each of four groups; (c) abundance of *Helicobacter* in each of four groups. Data are mean \pm SD ($n = 6$). Without a common letter mark indicates significant differences ($P < 0.05$).

experiment, claudin-1 and occludin decreased significantly after ETEC challenge, while ZO-1 also showed a decreasing trend in mice, indicating that ETEC destroyed the intestinal barrier in mice. In contrast, *L. plantarum* and *L. brevis* increased the expression of the tight junction protein in mice challenged by ETEC. And the protective effect of *L. brevis* on the barrier function of mice was slightly higher than that of

L. plantarum. Lysozyme is a critical bacteriostatic protein that strongly inhibits gram-positive bacteria [40], and cryptidin has a significant therapeutic effect on mice infected with *Salmonella Typhimurium* [41]. Therefore, the increase of these two substances in mice treated with *L. plantarum* and *L. brevis* may inhibit the growth of pathogenic bacteria and protect the health of mice.

There are lots of microbiota in the intestinal ecosystem, which play a significant role in host immunity and disease prevention. Therefore, unstable intestinal ecology may cause many diseases, such as ulcerative colitis and chronic diarrhea [42, 43]. ETEC reduced the intestinal microbial diversity of mice, while *L. plantarum* and *L. brevis* restored it to the normal level. The PD-whole-tree index of mice treated with *L. plantarum* was significantly higher than that of mice only challenged by ETEC, but there was no significant difference in the Shannon index. However, the results of mice treated with *L. brevis* showed the opposite results. This indicates that these two probiotics have almost the same effect on the recovery of intestinal microbial diversity in mice.

Proteobacteria is known to be the most disease-related intestinal microorganism, causing metabolic diseases and intestinal inflammation [44–46]. In this phylum, most microorganisms are human pathogens. Our study found that both *L. plantarum* and *L. brevis* inhibited the increase of *Proteobacteria* caused by ETEC significantly and made it return to the normal level, thus reducing the risk of intestinal inflammation in mice. Both *Clostridia* and *Epsilonproteobacteria* are pernicious bacteria that can cause digestive tract diseases in children. Tissue infection and intestinal diseases are often caused when those two bacteria enter the body of humans and other animals [47, 48]. *Clostridia* is involved in the development of necrotizing enterocolitis, which is a digestive tract disease that can threaten the life of preterm neonates [47]. In this study, mice treated with *L. plantarum* and *L. brevis* decreased the abundance of *Clostridia* and *Epsilonproteobacteria*, as well as a lower risk of digestive tract disease. As we all know, *Lactobacillus* is a probiotic with the function of preventing infection, reducing incidences of diarrhea, and improving production performance [49]. Some microorganisms of this genus, such as *Lactobacillus rhamnosus* and *Lactobacillus reuteri*, can protect the tight junctional protein after infection and contribute to the gut barrier function [50, 51]. In this experiment, both *L. plantarum* and *L. brevis* increased the abundance of *Lactobacillus* significantly, which may contribute to the gut barrier function and protection against inflammation. *Helicobacter* is the most common source of infection in the world, and it is the main risk factor of gastric cancer. Due to the ability to adapt to extreme acidic environment, *Helicobacter* can establish persistent infection and relieve the regulatory function of the host, leading to the pathogenesis and cancer of the digestive tract [52]. *L. plantarum* and *L. brevis* inhibited the growth of such pathogenic bacteria significantly and reduced the risk of canceration in tissue. It can be seen from the results that there is no significant difference between *L. plantarum* and *L. brevis* in promoting the abundance of probiotics and inhibiting that of pathogenic bacteria, indicating that they have almost the same effects on inhibiting intestinal inflammation and canceration.

5. Conclusion

The results in this experiment showed that *L. plantarum* and *L. brevis* can prevent the weight loss and intestinal injury caused by ETEC effectively, reduce the production of inflam-

matory factors, and strengthen the intestinal barrier function. Moreover, both of these two probiotics can stabilize the microbial community structure of intestine in mice, increase the abundance of probiotics such as *Lactobacillus*, and reduce the abundance of pathogenic bacteria such as *Proteobacteria*, *Clostridia*, *Epsilonproteobacteria*, and *Helicobacter*. Therefore, *L. plantarum* and *L. brevis* showed similarly effective inhibition on intestinal injury induced by ETEC and the ability to improve immune function. In summary, the feasibility and effectiveness of *L. plantarum* and *L. brevis* in the treatment of intestinal inflammation are demonstrated in our study, which provides a basis for further study of these two probiotics and their impact on intestinal inflammation such as diarrhea and colon cancer.

Data Availability

The data of this study is available from the correspondence authors upon reasonable request.

Conflicts of Interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Acknowledgments

This research was supported by the National Natural Science Foundation of China (Nos. 31772642, 31672457, and 41807135), Local Science and Technology Development Project Guided by the Central Government (YDZX2018 4300002303), Hunan Provincial Science and Technology Department (2019TP2004, 2018WK4025, 2020NK2004, 2020ZL2004, 2016NK2101, 2016TP2005, and 2018CT5002), China Postdoctoral Science Foundation (2018M632963 and 2019T120705), Scientific Research Fund of Hunan Provincial Education Department (2020JGYB112 and 18B107), Double First-Class Construction Project of Hunan Agricultural University (SYL201802003, YB2018007, and CX20190497), and Natural Science Foundation of Hunan Province, China (No. 2019JJ50220).

References

- [1] K. M. Yang, Z. Y. Jiang, C. T. Zheng, L. Wang, and X. F. Yang, “Effect of *Lactobacillus plantarum* on diarrhea and intestinal barrier function of young piglets challenged with enterotoxigenic *Escherichia coli* K88,” *Journal of Animal Science*, vol. 92, no. 4, pp. 1496–1503, 2014.
- [2] J. M. Fairbrother, E. Nadeau, and C. L. Gyles, “*Escherichia coli* in postweaning diarrhea in pigs: an update on bacterial types, pathogenesis, and prevention strategies,” *Animal Health Research Reviews*, vol. 6, no. 1, pp. 17–39, 2005.
- [3] J. Guignot, C. Chaplais, M. H. Coconnier-Polter, and A. L. Servin, “The secreted autotransporter toxin, sat, functions as a virulence factor in Afa/Dr diffusely adhering *Escherichia coli* by promoting lesions in tight junction of polarized epithelial cells,” *Cellular Microbiology*, vol. 9, no. 1, pp. 204–221, 2007.

- [4] J. A. Guttman, Y. Li, M. E. Wickham, W. Deng, A. W. Vogl, and B. B. Finlay, "Attaching and effacing pathogen-induced tight junction disruption in vivo," *Cellular Microbiology*, vol. 8, no. 4, pp. 634–645, 2006.
- [5] S. H. Kwak, Y. M. Cho, G. M. Noh, and A. S. Om, "Cancer preventive potential of kimchi lactic acid bacteria (*Weissella cibaria*, *Lactobacillus plantarum*)," *Journal of cancer prevention*, vol. 19, no. 4, pp. 253–258, 2014.
- [6] B. Le and S. H. Yang, "Efficacy of *Lactobacillus plantarum* in prevention of inflammatory bowel disease," *Toxicology Reports*, vol. 5, pp. 314–317, 2018.
- [7] C. Stevenson, R. Blaauw, E. Fredericks, J. Visser, and S. Roux, "Randomized clinical trial: Effect of *Lactobacillus plantarum* 299 v on symptoms of irritable bowel syndrome," *Nutrition*, vol. 30, no. 10, pp. 1151–1157, 2014.
- [8] P. Trevisi, R. Latorre, D. Priori et al., "Effect of feed supplementation with live yeast on the intestinal transcriptome profile of weaning pigs orally challenged with *Escherichia coli* F4," *Animal: an international journal of animal bioscience*, vol. 11, no. 1, pp. 33–44, 2017.
- [9] G. Y. Yang, Y. H. Zhu, W. Zhang, D. Zhou, C. C. Zhai, and J. F. Wang, "Influence of orally fed a select mixture of *Bacillus* probiotics on intestinal T-cell migration in weaned MUC4 resistant pigs following *Escherichia coli* challenge," *Veterinary Research*, vol. 47, no. 1, p. 71, 2016.
- [10] J. Villena, E. Chiba, M. G. Vizoso-Pinto et al., "Immunobiotic *Lactobacillus rhamnosus* strains differentially modulate antiviral immune response in porcine intestinal epithelial and antigen presenting cells," *BMC Microbiology*, vol. 14, no. 1, p. 126, 2014.
- [11] O. Farkas, G. Mátis, E. Pászti-Gere et al., "Effects of *Lactobacillus plantarum* 2142 and sodium n-butyrate in lipopolysaccharide-triggered inflammation: comparison of a porcine intestinal epithelial cell line and primary hepatocyte monocultures with a porcine enterohepatic co-culture system," *Journal of Animal Science*, vol. 92, no. 9, pp. 3835–3845, 2014.
- [12] P. Yu, C. Ke, J. Guo, X. Zhang, and B. Li, "Lactobacillus plantarum L15 alleviates colitis by inhibiting LPS-mediated NF- κ B activation and ameliorates DSS-induced gut microbiota dysbiosis," *Frontiers in Immunology*, vol. 11, p. 575173, 2020.
- [13] R. Pieper, P. Janczyk, V. Uruschurov, U. Korn, B. Pieper, and W. B. Souffrant, "Effect of a single oral administration of *Lactobacillus plantarum* DSMZ 8862/8866 before and at the time point of weaning on intestinal microbial communities in piglets," *International Journal of Food Microbiology*, vol. 130, no. 3, pp. 227–232, 2009.
- [14] J. Wang, H. F. Ji, S. X. Wang et al., "Lactobacillus plantarum ZLP001: in vitro assessment of antioxidant capacity and effect on growth performance and antioxidant status in weaning piglets," *Asian-Australasian Journal of Animal Sciences*, vol. 25, no. 8, pp. 1153–1158, 2012.
- [15] M. Kassayová, N. Bobrov, L. Strojny et al., "Anticancer and immunomodulatory effects of *Lactobacillus plantarum* LS/07, inulin and melatonin in NMU-induced rat model of breast cancer," *Anticancer Research*, vol. 36, no. 6, pp. 2719–2728, 2016.
- [16] L. O. Chuah, H. L. Foo, T. C. Loh et al., "Postbiotic metabolites produced by *Lactobacillus plantarum* strains exert selective cytotoxicity effects on cancer cells," *BMC Complementary and Alternative Medicine*, vol. 19, no. 1, p. 114, 2019.
- [17] E. Rönkä, E. Malinen, M. Saarela, M. Rinta-Koski, J. Aarnikunnas, and A. Palva, "Probiotic and milk technological properties of *Lactobacillus brevis*," *International Journal of Food Microbiology*, vol. 83, no. 1, pp. 63–74, 2003.
- [18] R. Kant, J. Blom, A. Palva, R. J. Siezen, and W. M. de Vos, "Comparative genomics of *Lactobacillus*," *Microbial Biotechnology*, vol. 4, no. 3, pp. 323–332, 2011.
- [19] N. Fuke, T. Takagi, Y. Higashimura et al., "Lactobacillus brevis KB290 with vitamin a ameliorates murine intestinal inflammation associated with the increase of CD11c+ macrophage/CD103- dendritic cell ratio," *Inflammatory Bowel Diseases*, vol. 24, no. 2, pp. 317–331, 2018.
- [20] N. Ueno, M. Fujiya, S. Segawa et al., "Heat-killed body of lactobacillus brevis SBC8803 ameliorates intestinal injury in a murine model of colitis by enhancing the intestinal barrier function," *Inflammatory Bowel Diseases*, vol. 17, no. 11, pp. 2235–2250, 2011.
- [21] Y. Ma, C. Hu, W. Yan, H. Jiang, and G. Liu, "Lactobacillus pentosus increases the abundance of Akkermansia and affects the serum metabolome to alleviate DSS-induced colitis in a murine model," *Frontiers in cell and developmental biology*, vol. 8, p. 591408, 2020.
- [22] W. Ren, J. Yin, M. Wu et al., "Serum amino acids profile and the beneficial effects of L-arginine or L-glutamine supplementation in dextran sulfate sodium colitis," *PLoS One*, vol. 9, no. 2, article e88335, 2014.
- [23] Y. Ma, H. Jiang, J. Fang, and G. Liu, "IRW and IQW reduce colitis-associated cancer risk by alleviating DSS-induced colonic inflammation," *BioMed Research International*, vol. 2019, Article ID 6429845, 9 pages, 2019.
- [24] V. Liévin-Le Moal, "Dysfunctions at human intestinal barrier by water-borne protozoan parasites: lessons from cultured human fully differentiated colon cancer cell lines," *Cellular Microbiology*, vol. 15, no. 6, pp. 860–869, 2013.
- [25] S. Ding, Y. Ma, G. Liu, W. Yan, H. Jiang, and J. Fang, "Lactobacillus brevis alleviates DSS-induced colitis by reprogramming intestinal microbiota and influencing serum metabolome in murine model," *Frontiers in Physiology*, vol. 10, p. 1152, 2019.
- [26] V. Liévin-Le Moal and A. L. Servin, "The front line of enteric host defense against unwelcome intrusion of harmful microorganisms: mucins, antimicrobial peptides, and microbiota," *Clinical Microbiology Reviews*, vol. 19, no. 2, pp. 315–337, 2006.
- [27] Y. Ma, G. Liu, M. Tang, J. Fang, and H. Jiang, "Epigallocatechin gallate can protect mice from acute stress induced by LPS while stabilizing gut microbes and serum metabolites levels," *Frontiers in Immunology*, vol. 12, p. 640305, 2021.
- [28] Y. Hou, L. Wang, W. Zhang et al., "Protective effects of N-acetylcysteine on intestinal functions of piglets challenged with lipopolysaccharide," *Amino Acids*, vol. 43, no. 3, pp. 1233–1242, 2012.
- [29] H. Liu, J. Zhang, S. Zhang et al., "Oral administration of *Lactobacillus fermentum* I5007 favors intestinal development and alters the intestinal microbiota in formula-fed piglets," *Journal of Agricultural and Food Chemistry*, vol. 62, no. 4, pp. 860–866, 2014.
- [30] C. Suo, Y. Yin, X. Wang et al., "Effects of lactobacillus plantarum ZJ316 on pig growth and pork quality," *BMC Veterinary Research*, vol. 8, no. 1, p. 89, 2012.
- [31] S. C. Tsai, M. Noda, R. Adamik, J. Moss, and M. Vaughan, "Enhancement of cholera toxin ADP-ribosyltransferase activities

- by guanyl nucleotides and a 19-kDa membrane protein,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 84, no. 15, pp. 5139–5142, 1987.
- [32] X. Wang, X. Gao, and P. R. Hardwidge, “Heat-labile enterotoxin-induced activation of NF- κ B and MAPK pathways in intestinal epithelial cells impacts enterotoxigenic *Escherichia coli* (ETEC) adherence,” *Cellular Microbiology*, vol. 14, no. 8, pp. 1231–1241, 2012.
- [33] L. Petecchia, F. Sabatini, C. Usai, E. Caci, L. Varesio, and G. A. Rossi, “Cytokines induce tight junction disassembly in airway cells via an EGFR-dependent MAPK/ERK1/2-pathway,” *Laboratory investigation; a journal of technical methods and pathology*, vol. 92, no. 8, pp. 1140–1148, 2012.
- [34] L. Huang, Z. Zhao, C. Duan et al., “*Lactobacillus plantarum* C88 protects against aflatoxin B1-induced liver injury in mice via inhibition of NF- κ B-mediated inflammatory responses and excessive apoptosis,” *BMC Microbiology*, vol. 19, no. 1, p. 170, 2019.
- [35] T. Lahteinen, A. Lindholm, T. Rintila et al., “Effect of *Lactobacillus brevis*_ ATCC 8287 as a feeding supplement on the performance and immune function of piglets,” *Veterinary Immunology and Immunopathology*, vol. 158, no. 1-2, pp. 14–25, 2014.
- [36] M. Roselli, A. Finamore, M. S. Britti et al., “The novel porcine *Lactobacillus sobrius* strain protects intestinal cells from enterotoxigenic *Escherichia coli* K88 infection and prevents membrane barrier damage,” *The Journal of Nutrition*, vol. 137, no. 12, pp. 2709–2716, 2007.
- [37] A. M. Johnson, R. S. Kaushik, and P. R. Hardwidge, “Disruption of transepithelial resistance by enterotoxigenic *Escherichia coli*,” *Veterinary Microbiology*, vol. 141, no. 1-2, pp. 115–119, 2010.
- [38] M. Roselli, A. Finamore, I. Garaguso, M. S. Britti, and E. Mengheri, “Zinc oxide protects cultured enterocytes from the damage induced by *Escherichia coli*,” *The Journal of Nutrition*, vol. 133, no. 12, pp. 4077–4082, 2003.
- [39] Y. Wu, C. Zhu, Z. Chen et al., “Protective effects of *Lactobacillus plantarum*_ on epithelial barrier disruption caused by enterotoxigenic *Escherichia coli*_ in intestinal porcine epithelial cells,” *Veterinary Immunology and Immunopathology*, vol. 172, pp. 55–63, 2016.
- [40] T. Wu, Q. Jiang, D. Wu et al., “What is new in lysozyme research and its application in food industry? A review,” *Food Chemistry*, vol. 274, pp. 698–709, 2019.
- [41] P. Rishi, A. Bhogal, S. Arora, S. K. Pandey, I. Verma, and I. P. Kaur, “Improved oral therapeutic potential of nanoencapsulated cryptdin formulation against *Salmonella* infection,” *European Journal of Pharmaceutical Sciences: Official Journal of the European Federation for Pharmaceutical Sciences*, vol. 72, pp. 27–33, 2015.
- [42] R. C. Vemuri, R. Gundamaraju, T. Shinde, and R. Eri, “Therapeutic interventions for gut dysbiosis and related disorders in the elderly: antibiotics, probiotics or faecal microbiota transplantation?,” *Beneficial Microbes*, vol. 8, no. 2, pp. 179–192, 2017.
- [43] I. Garcia-Mantrana, M. Selma-Royo, C. Alcantara, and M. C. Collado, “Shifts on gut microbiota associated to Mediterranean diet adherence and specific dietary intakes on general adult population,” *Frontiers in Microbiology*, vol. 9, p. 890, 2018.
- [44] N. R. Shin, T. W. Whon, and J. W. Bae, “Proteobacteria: microbial signature of dysbiosis in gut microbiota,” *Trends in Biotechnology*, vol. 33, no. 9, pp. 496–503, 2015.
- [45] D. N. Frank, A. L. St Amand, R. A. Feldman, E. C. Boedeker, N. Harpaz, and N. R. Pace, “Molecular-phylogenetic characterization of microbial community imbalances in human inflammatory bowel diseases,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 104, no. 34, pp. 13780–13785, 2007.
- [46] R. B. Sartor, “Microbial influences in inflammatory bowel diseases,” *Gastroenterology*, vol. 134, no. 2, pp. 577–594, 2008.
- [47] S. Schonherr-Hellec and J. Aires, “Clostridia and necrotizing enterocolitis in preterm neonates,” *Anaerobe*, vol. 58, pp. 6–12, 2019.
- [48] O. Vandenberg, A. J. Cornelius, H. Souayah et al., “The role of Epsilonproteobacteria in children with gastroenteritis,” *The Pediatric Infectious Disease Journal*, vol. 32, no. 10, pp. 1140–1142, 2013.
- [49] J. F. Koninkx and J. J. Malago, “The protective potency of probiotic bacteria and their microbial products against enteric infections-review,” *Folia Microbiologica*, vol. 53, no. 3, pp. 189–194, 2008.
- [50] B. P. Blackwood, C. Y. Yuan, D. R. Wood, J. D. Nicolas, J. S. Grothaus, and C. J. Hunter, “Probiotic *Lactobacillus* species strengthen intestinal barrier function and tight junction integrity in experimental necrotizing Enterocolitis,” *Journal of probiotics & health*, vol. 5, no. 1, 2017.
- [51] F. Yang, A. Wang, X. Zeng, C. Hou, H. Liu, and S. Qiao, “*Lactobacillus reuteri* I5007 modulates tight junction protein expression in IPEC-J2 cells with LPS stimulation and in newborn piglets under normal conditions,” *BMC Microbiology*, vol. 15, no. 1, p. 32, 2015.
- [52] V. Camilo, T. Sugiyama, and E. Touati, “Pathogenesis of *Helicobacter pylori* infection,” *Helicobacter*, vol. 22, Supplement 1, 2017.